← Issue №18/ week of Nov 1, 2026/ the whole section, in full

Esophagus/Reflux, in full.

All 4 Esophagus/Reflux papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 4, in full

most clinically useful first
Esophagus/Reflux prospective cohort · Oct 30, 2026 · J Neurogastro Motil · IF 3.4

Eosinophilic Esophagitis in Asia: Distinct Clinical Phenotypes and Implications for Long-Term Management.

New evidenceeosinophilic esophagitisepidemiologyproton pump inhibitors
Clinical takeawayNo change in maintenance practice from this review: the authors ask whether every patient needs lifelong maintenance but present no data on outcomes after stopping therapy.
What it foundAsian studies report lower rates of fibrostenotic complications, greater response to PPIs and potassium-competitive acid blockers, and frequent asymptomatic esophageal eosinophilia found at screening endoscopy; molecular studies suggest the underlying biology matches Western EoE.
ContextThe authors attribute the regional differences partly to disease stage at diagnosis, screening practice, healthcare systems and environment rather than to a different disease.
Measured against the standard of care· ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417)

Decision at stakewhether all patients with EoE require universal lifelong maintenance therapy

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

ACG 2025 (GRADE) is still the governing guideline. The ASGE 2026 consensus Part 2 (modified Delphi, 28 statements at ≥80% agreement; not GRADE) adds endoscopic and pediatric detail without contradicting it. DIAGNOSIS: symptoms of esophageal dysfunction plus ≥15 eos/hpf after excluding other causes of esophageal eosinophilia. A PPI trial is not a diagnostic criterion (PPI-REE abandoned). Do the initial diagnostic EGD off PPI, topical steroid and dietary therapy (ACG key concept; ASGE consensus, which gives no washout duration). Initial assessment is a standard EGD, not a less-invasive modality, so that full biopsies and dilation are possible (ASGE). Take ≥6 esophageal biopsies from ≥2 levels in anyone with symptoms or endoscopic findings consistent with EoE, targeting visible lesions. In CHILDREN with suspected EoE, also biopsy the stomach and duodenum (ASGE). Use EREFS at every endoscopy and report a quantified peak eosinophil count (ACG strong/low; ASGE). TREATMENT (ACG): swallowed topical steroids STRONG/moderate; high-dose PPI CONDITIONAL/low; empiric elimination diet CONDITIONAL/low. Choose a single initial therapy by shared decision-making. Fluticasone or budesonide are both reasonable. Adult doses: PPI double the reflux dose (e.g., omeprazole 20 mg BID or 40 mg daily); budesonide 2-4 mg/day (BOS 2 mg BID); fluticasone 1,760 mcg/day divided. Pediatric doses: PPI 2 mg/kg/day; budesonide 1-2 mg/day; fluticasone 110-880 mcg/day. Allergy testing is not used to direct diets. A 1FED/2FED step-up diet with a dietitian is acceptable, with endoscopic and biopsy confirmation after each reintroduced food. Dupilumab is CONDITIONAL for PPI-nonresponsive patients aged ≥12 (moderate) and for ages 1-11 at ≥15 kg (low). Weight-band dosing: 15-<30 kg 200 mg q2w; 30-<40 kg 300 mg q2w; ≥40 kg 300 mg weekly. Recommendations AGAINST: omalizumab, cromolyn, montelukast. No recommendation for cendakimab, benralizumab, lirentelimab, mepolizumab or reslizumab. DILATION: an adjunct to anti-inflammatory therapy for strictures causing dysphagia (ACG conditional/low). Start low and go slow; target ≥16 mm in adults and adolescents over ≥1 session. In children, ASGE supports dilation of symptomatic strictures or a narrow-caliber esophagus regardless of disease activity, using the same start-low/go-slow approach. MAINTENANCE: continue effective therapy (ACG STRONG despite low evidence) at the lowest effective dose. MONITORING: judge response on symptoms, endoscopy and histology together, never symptoms alone. Assess response endoscopically at 8-12 weeks after starting a PPI or topical steroid. For diet, ACG says 8-12 weeks and ASGE says 6-8 weeks. For dupilumab or biologics, assess at 12-24 weeks (ASGE: up to 24 weeks). Allow appropriate washout or timing after any treatment change before the follow-up EGD (ASGE). Take monitoring biopsies from the most severe-appearing lesions (rings, furrows, exudates) (ASGE). Monitoring biopsies may be limited to the esophagus when prior gastric and duodenal biopsies were normal and nothing new suggests other pathology (ASGE). The histologic response threshold of <15 eos/hpf is a 'may consider' target, read alongside endoscopic and symptom findings. Shorten follow-up after complications. Care gaps of ≥2 years are associated with fibrostenosis. PEDIATRIC (ACG): esophagram for children with dysphagia to assess fibrostenotic disease; feeding therapy and dietitian for feeding dysfunction; growth, development and nutrition are treatment goals.

ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417) · reviewed 2026-10-11 ↗
Jung KW, Dellon ES · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
Esophagus/Reflux retrospective · n=456 · Oct 30, 2026 · J Neurogastro Motil · IF 3.4

Hiatal Hernia and Conclusive Gastroesophageal Reflux Disease: Size Matters.

Practice-changingGERDproton pump inhibitorsesophageal motility
Clinical takeawayIn patients with suspected GERD and inconclusive initial findings, assess HH size as an additional anatomical marker to inform diagnostic confidence using Lyon Consensus 2.0 criteria.
What it foundPathological acid exposure time (AET) increased stepwise with hiatal hernia (HH) size: 19.3% in no HH, 41.2% in small HH (<3 cm), 51.3% in medium HH (3-5 cm), and 83.0% in large HH (>5 cm).
ContextSupports the Lyon Consensus by demonstrating a strong correlation between HH size and GERD severity, suggesting HH size may enhance diagnostic precision.
Refinessuggested applicable standard· British Society of Gastroenterology-endorsed international consensus, "Updates to the modern diagnosis of GERD: Lyon consensus 2.0" (Gyawali CP, Yadlapati R, Fass R, et al.), Gut, 2024

Decision at stakethe role of hiatal hernia size in assessing GERD using Lyon Consensus 2.0 criteria

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

For heartburn or regurgitation persisting despite PPI therapy, current practice (ACG 2022 GERD guideline, still the operative ACG guideline, plus the AGA 2022 personalized-GERD CPU) is to first optimize the PPI: confirm adherence, dose 30-60 minutes before meals, escalate to twice-daily dosing or switch agents for an 8-week trial. Empiric escalation to vonoprazan/P-CAB is NOT a routine pre-testing step: the AGA 2024 P-CAB clinical practice update advises against P-CABs as first-line therapy and reserves them for PPI failure with confirmatory GERD evidence (LA grade B or worse erosive esophagitis, biopsy-proven Barrett's, peptic stricture, or acid exposure time >6%). If symptoms persist after optimization, perform EGD (ideally 2-4 weeks off PPI when GERD is unproven) with esophageal biopsies to exclude EoE (>=15 eos/hpf; the ACG 2025 EoE guideline has removed the PPI trial from the diagnostic pathway) and then physiologic testing per Lyon Consensus 2.0: in unproven GERD, ambulatory reflux monitoring OFF therapy, applying Lyon 2.0's modality-specific thresholds -- on catheter-based single-day (24-hour) pH or pH-impedance, AET >6% is conclusive for GERD, 4-6% is inconclusive, and <4% argues against GERD; on prolonged wireless (Bravo, up to 96-hour) monitoring, AET >6% on >=2 days is conclusive for GERD while AET <4% on all days excludes it, and a study meeting neither threshold is inconclusive (the number of days with AET <4% carries prognostic weight for PPI discontinuation) -- and, in either modality, a normal-AET (<4%) study with positive symptom association indicates reflux hypersensitivity or, without it, functional heartburn; in previously proven GERD, pH-impedance ON optimized therapy, where AET >4% plus >80 reflux episodes defines actionable refractory GERD (MNBI <1500 ohms supportive, >2300 ohms against). High-resolution manometry per Chicago Classification 4.0 (still current) excludes achalasia and major motility disorders and is required before anti-reflux surgery. Therapy is phenotype-directed: surgical or endoscopic anti-reflux intervention for confirmed refractory pathologic reflux, and neuromodulators with or without brain-gut behavioral therapy for reflux hypersensitivity and functional heartburn.

British Society of Gastroenterology-endorsed international consensus, "Updates to the modern diagnosis of GERD: Lyon consensus 2.0" (Gyawali CP, Yadlapati R, Fass R, et al.), Gut, 2024 · reviewed 2026-07-23 ↗
Hernández JS … Gyawali CP · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
Esophagus/Reflux prospective cohort · n=20,402 · Oct 29, 2026 · J Gastroenterology · IF 5.7

Columnar-lined esophagus measuring less than 1 cm as a risk factor for esophageal squamous cell carcinoma in Japanese men.

New evidenceesophageal cancerBarrett's esophagusepidemiologybiomarker
Clinical takeawayIn 20,402 men at health check-ups, ultra-short-segment BE was linked to later ESCC; the authors present this as a first association, with the gastric atrophy subgroup needing validation, not as a surveillance indication.
What it foundUltra-short-segment Barrett's esophagus (USSBE; <1 cm) was independently associated with esophageal squamous cell carcinoma (ESCC) (adjusted HR 1.82, 95% CI 1.03-3.24), with higher risk in those with extensive gastric atrophy (adjusted HR 2.40, 95% CI 1.13-5.13).
ContextChallenges prior assumptions by identifying USSBE as a novel risk factor for ESCC, especially in the context of extensive gastric atrophy, which was not previously recognized.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Watanabe K … Iijima K · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
Esophagus/Reflux meta analysis · n=34,123 · Oct 28, 2026 · Aliment Pharm Ther · IF 6.7

Meta-Analysis: Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastroprotection in Patients Receiving Antiplatelet Therapy.

New evidencemeta-analysisproton pump inhibitors
Clinical takeawayNo clinical action yet: findings on MACE and revascularisation are from observational studies and require confirmation in randomised trials.
What it foundP-CABs showed no statistically significant difference from PPIs in gastrointestinal bleeding (RR 0.89, 95% CI 0.67-1.18), but observational studies suggested lower MACE (RR 0.80, 0.65-0.98) and revascularisation (RR 0.77, 0.59-0.99) rates with P-CABs.
ContextConfirms PPIs remain standard for gastroprotection during antiplatelet therapy; observational data suggest potential cardiovascular benefits with P-CABs, but evidence is insufficient to change practice.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Mansk PG … Mahajan K · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Back to issue №18 Every section of this issue is one click away, at the top of this page. Follow Esophagus/Reflux by RSS